Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
56°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silo Pharma Inc
(NQ:
SILO
)
1.770
-0.080 (-4.32%)
Streaming Delayed Price
Updated: 11:16 AM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silo Pharma Inc
< Previous
1
2
3
4
Next >
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
March 15, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression
March 13, 2023
Via
Investor Brand Network
Exposures
COVID-19
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions
March 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders
February 22, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s
February 13, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
February 13, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes
February 07, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Announces Expansion of Intellectual Property Portfolio
February 02, 2023
Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program
January 31, 2023
Via
Investor Brand Network
Silo Pharma Announces Stock Repurchase Program
January 31, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial
January 26, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide
January 20, 2023
Via
Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis
January 12, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Clinical Study Examining Psilocybin’s Effect on Inflammation
January 10, 2023
Via
Investor Brand Network
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study
January 03, 2023
Via
Investor Brand Network
Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
December 30, 2022
Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics
Via
Spotlight Growth
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
December 30, 2022
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END
Via
FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU
December 30, 2022
21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December...
Via
FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
December 30, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter
December 01, 2022
Via
Investor Brand Network
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
December 01, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
November 21, 2022
Via
Investor Brand Network
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
November 21, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
November 11, 2022
Via
Investor Brand Network
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
November 11, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
New Psychedelic Journal to Focus on Publishing Psychedelic Research
November 07, 2022
Via
Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
November 04, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
November 03, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.